Evidence map›Paper›PMID 30762599›Full record

ArticleDiseases of the colon and rectum2019

Sex Differences in Treatment Strategies Among Patients With Ulcerative Colitis: A Retrospective Cohort Analysis of Privately Insured Patients.

Lindsay A Sceats, Arden M Morris, M Kate Bundorf, K T Park, Cindy Kin

Open access · greenAbstract readVideo-Audio Media
In one paragraph

Article in Diseases of the colon and rectum, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Influence of biological sex in inflammatory bowel diseases.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Sex-based differences in inflammatory bowel diseases: a review.Therapeutic advances in gastroenterology · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lindsay A SceatsS-SPIRE Center, Department of Surgery, Stanford University, Stanford, California.
Arden M MorrisS-SPIRE Center, Department of Surgery, Stanford University, Stanford, California.
M Kate BundorfStanford University, Department of Health Research and Policy, Stanford, California.
K T ParkInflammatory Bowel Disease Center, Department of Pediatrics (Gastroenterology), Stanford University, Stanford, California.
Cindy KinS-SPIRE Center, Department of Surgery, Stanford University, Stanford, California.
Stanford University · USStanford Health Care · US

Funding

Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
Spectrum Stanford Center for clinical and Translational Research and EducationKL2TR001083 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$4.9M
NCATS NIH HHS KL2 TR001083NCATS NIH HHS UL1 TR001085NCATS NIH HHS UL1 TR003142
6 · The paper itself

Abstract

backgroundSex-based treatment disparities occur in many diseases. Women undergo fewer procedural interventions, and their care is less consistent with guideline-based therapy. There is limited research exploring sex-based differences in ulcerative colitis treatment. We hypothesized that women are less likely to be treated with strategies consistent with long-term disease remission, including surgery and maintenance medications.

objectiveThe aim of this study was to determine if patient sex is associated with choice of treatment strategy for ulcerative colitis.

designThis is a retrospective cohort analysis.

settingData were gathered from a large commercial insurance claims database from 2007 to 2015. PATIENTS: We identified a cohort of 38,851 patients newly diagnosed with ulcerative colitis, aged 12 to 64 years with at least 1 year of follow-up.

main outcome measuresThe primary outcomes measured were the differences between male and female patients in 1) rates and types of index ulcerative colitis operations, 2) rates and types of ulcerative colitis medication prescriptions, and 3) rates of opioid prescriptions.

resultsMen were more likely to undergo surgical treatment for ulcerative colitis (2.94% vs 1.97%, p < 0.001, OR 1.51, p < 0.001). The type of index operation performed did not vary by sex. Men were more likely to undergo treatment with maintenance medications, including biologic (12.4% vs 10.2%, p < 0.001, OR 1.22, p < 0.001), immunomodulatory (16.3% vs 14.9%, p < 0.001, OR 1.08, p = 0.006), and 5-aminosalicylate medications (67.0% vs 63.2%, p < 0.001, OR 1.18, p < 0.001). Women were more likely to undergo treatment with rescue therapies and symptomatic control with corticosteroids (55.5% vs 54.0%, p = 0.002, OR 1.07, p = 0.002) and opioids (50.2% vs 45.9%, p < 0.001, OR 1.17, p < 0.001). LIMITATIONS: Claims data lack clinical characteristics acting as confounders.

conclusionsMen with ulcerative colitis were more likely to undergo treatment consistent with long-term remission or cure, including maintenance medications and definitive surgery. Women were more likely to undergo treatment consistent with short-term symptom management. Further studies to explore underlying mechanisms of sex-related differences in ulcerative colitis treatment strategies and disease trajectories are warranted. See Video Abstract at http://links.lww.com/DCR/A943.

Indexed as

AdolescentAdrenal Cortex HormonesAdultAnti-Inflammatory Agents, Non-SteroidalChildCohort StudiesColectomyColitis, UlcerativeFemaleHumansIleostomyImmunologic FactorsImmunosuppressive AgentsMaleMesalamineMiddle AgedAdrenal Cortex HormonesAnti-Inflammatory Agents, Non-SteroidalImmunologic FactorsImmunosuppressive AgentsMesalamine

Identifiers

PMID30762599
PMCPMC6456369
OpenAlexW2916195981

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.